Viewray (VRAY) Receives a Buy from B.Riley FBR

B.Riley FBR analyst Andrew D’silva reiterated a Buy rating on Viewray (VRAY) today and set a price target of $13.75. The company’s shares opened today at $7.63.

D’silva commented:

“ViewRay (VRAY) reported 3Q18 results AMC 11/8 and posted top line/adj. EPS of $17.7M/ ($0.21) vs. our/consensus estimates of $18.7M/($0.21) and $17.8M/($0.22), respectively. The slight top-line miss was tied to MRIdian early adopter ASP fluctuations as our expectation for three installs was met. While our adj. EPS estimate was accurate, GAAP EPS of ($0.39) was below our ($0.31). Since VRAY doesn’t provide adjusted figures, we believe we are one of the only firms providing adj. EPS projections materially different than GAAP EPS prior to the print. Thus, other firms could note VRAY’s bottom-line miss was significantly greater than our adj. EPS comparison. The primary difference between VRAY’s and our GAAP EPS were ~$5M in severance charges and ~$3M in one-time expenses that impacted GMs.”

According to, D’silva is a 4-star analyst with an average return of 14.9% and a 49.5% success rate. D’silva covers the Healthcare sector, focusing on stocks such as Cumberland Pharmaceuticals Inc., Sorrento Therapeutics, and Kindred Biosciences.

Currently, the analyst consensus on Viewray is a Strong Buy with an average price target of $14.94, implying a 95.8% upside from current levels. In a report released today, Mizuho Securities also maintained a Buy rating on the stock.


See today’s analyst top recommended stocks >>

The company has a one-year high of $13.21 and a one-year low of $6.05. Currently, Viewray has an average volume of 1.51M.

Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ViewRay, Inc. engages in the research, development, and manufacture of magnetic resonance imaging (MRI) system. Its product includes MRIdian, which supports image-guided radiation therapy, stereotactic radiation therapy, and radiosurgery. The company was founded by Dinara Akzhigitova on September 6, 2013 and is headquartered in Oakwood Village, OH.